Insmed Inc (INSM)vsPropanc Biopharma, Inc. Common Stock (PPCB)
INSM
Insmed Inc
$136.00
-5.56%
HEALTHCARE · Cap: $31.17B
PPCB
Propanc Biopharma, Inc. Common Stock
$0.12
+1.45%
HEALTHCARE · Cap: $1.86M
Smart Verdict
WallStSmart Research — data-driven comparison
PPCB leads profitability with a 0.0% profit margin vs -210.5%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PPCB
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
N/A
Fair Value
$354.35
Current Price
$0.12
$354.23 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 152.6% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Trading at 39.4x book value
ROE of -249.3% — below average capital efficiency
Negative free cash flow — burning cash
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
The strongest argument for INSM centers on Revenue Growth. Revenue growth of 152.6% demonstrates continued momentum. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PPCB
The strongest argument for PPCB centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are EPS Growth, Price/Book, Return on Equity.
Bear Case : PPCB
The primary concerns for PPCB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a hypergrowth stock while PPCB is a value play — different risk/reward profiles.
PPCB carries more volatility with a beta of 3.48 — expect wider price swings.
INSM is growing revenue faster at 152.6% — sustainability is the question.
PPCB generates stronger free cash flow (-1M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 26/100) and 152.6% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Propanc Biopharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. The company is headquartered in Camberwell, Australia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?